Clinical Report: COSMIC-313 Study Final Results in Advanced Renal Cell Carcinoma

Overview

The COSMIC-313 study demonstrates a significant progression-free survival benefit with cabozantinib plus nivolumab and ipilimumab compared to placebo plus nivolumab and ipilimumab in previously untreated advanced renal cell carcinoma. No overall survival benefit was observed.

Background

Advanced renal cell carcinoma (RCC) remains a challenging condition with limited treatment options. The COSMIC-313 study aimed to evaluate the efficacy of combining cabozantinib with nivolumab and ipilimumab in this patient population. Understanding the impact of treatment combinations and biomarkers is crucial for optimizing therapeutic strategies in advanced RCC.

Data Highlights

Key Findings

• Cabozantinib plus nivolumab and ipilimumab resulted in a median PFS of 16.6 months.
• The placebo group had a median PFS of 11.2 months.
• No significant difference in median OS was observed (HR 1.02).
• Grade 3/4 treatment-related adverse events occurred in 75% of the triplet arm versus 43% in the doublet arm.
• Higher levels of M2-like macrophages were associated with improved PFS and OS in the triplet regimen.
• Responders in the triplet arm exhibited elevated angiogenic signatures.

Clinical Implications

The findings from the COSMIC-313 study indicate that cabozantinib enhances progression-free survival in advanced RCC, but overall survival rates are similar, and there is an increased incidence of severe adverse events.

Conclusion

The COSMIC-313 study reinforces the role of cabozantinib in improving progression-free survival in advanced renal cell carcinoma.

Related Resources & Content

1. Choueiri TK, Annals of Oncology, 2026 -- Cabozantinib Plus Nivolumab and Ipilimumab in Previously Untreated, Advanced Renal Cell Carcinoma: Final Results and Biomarker Analyses from the Phase III COSMIC-313 Study
2. dana-farber — Dana-Farber Research News 07.01.2025
3. dana-farber — Dana-Farber Research News 02.15.2026
4. dana-farber — Dana-Farber Research News 01.01.2026
5. dana-farber — Dana-Farber Research News 04.15.2026
6. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 | Journal of Clinical Oncology
7. Transdermal Estradiol Patches in Locally Advanced Prostate Cancer | New England Journal of Medicine
8. Patient-Clinician Communication: ASCO Guideline Update | Journal of Clinical Oncology